← Back to patent-cliff list
Dalzanemdor
Tier C — Watch / tradeDalzanemdor
Sage Therapeutics Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：NMDAR
Indications (approved)：Alzheimer's disease, Dementia, Mild cognitive impairment, Parkinson's disease, 亨廷顿舞蹈症
Regional status
US
Phase II
2020-07-31
EU
Discontinued
2022-12-14
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Dalzanemdor?
Approved indications include: Alzheimer's disease, Dementia, Mild cognitive impairment, Parkinson's disease, 亨廷顿舞蹈症.
When does the Dalzanemdor patent expire?
No public expiry year is available for Dalzanemdor yet; this page updates once verified.
How do I get a quote for Dalzanemdor intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06